FDA Awards 21 Grants for Rare Disease Product Development
More than $23 million will be awarded over the next four years. The grants have been award through the Orphan Products Clinical Trials Grants Program.
The U.S. Food and Drug Administration has announced 21 new research grants totaling more than $23 million during the next four years to drive development of products for patients with rare diseases. The grants were awarded to investigators in academics and industry.
"We are proud of our 30-year track record of fostering and encouraging the development of safe and effective therapies for rare diseases through our clinical trials grant program," said Dr. Gayatri R. Rao, M.D., J.D., director of FDA's Office of Orphan Product Development, within the Office of Special Medical Programs. "The grants awarded this year will support much-needed research in 21 different rare diseases, many of which have little, or no, available treatment options."
The grants have been award through the Orphan Products Clinical Trials Grants Program in order to encourage the clinical development of drugs, biologics, medical devices, or medical foods for use in rare diseases.